Form 4: Candel Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Paul Peter Tak, Chief Executive Officer and a Director of Candel Therapeutics, Inc., sold 280,245 shares of common stock on September 10, 2026.
Summary
- Option exercise/conversion: acquired 125,000 Common Stock at $1.55 ($193,750) on September 10, 2026; holds 393,566 after (Direct).
- Open-market sale: disposed of 220,866 Common Stock at $11.50 ($2,539,893) on September 10, 2026; holds 172,700 after (Direct).
- Open-market sale: disposed of 59,379 Common Stock at $10.46 ($620,891) on September 11, 2026; holds 113,321 after (Direct).
- Option exercise/conversion: disposed of 125,000 Stock Option (Right to Buy) on September 10, 2026; holds 1,638,968 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,160,783 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul Peter Tak — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Option exercise/conversion | Common Stock | 125,000 | $2 | $193.8K | 393,566 |
| 2026-09-10 | Open-market sale | Common Stock | 220,866 | $11 | $2.5M | 172,700 |
| 2026-09-11 | Open-market sale | Common Stock | 59,379 | $10 | $620.9K | 113,321 |
| 2026-09-10 | Option exercise/conversion | Stock Option (Right to Buy) | 125,000 | — | — | 1,638,968 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Option exercise/conversion (125,000 shares) |
| 2026-09-10 | Open-market sale (220,866 shares) |
| 2026-09-11 | Open-market sale (59,379 shares) |
| 2026-09-10 | Option exercise/conversion (125,000 shares) |
Keywords
insider transaction, Form 4, CADL, Candel Therapeutics, Inc., bearish, Paul Peter Tak
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.